210 likes | 327 Vues
This document outlines the Swiss perspective on marketing authorization for veterinary drugs, focusing on quality, efficacy, and safety in compliance with federal law. It highlights the science-driven approach adopted by Swiss regulatory bodies and discusses the regulatory landscape, including the VICH guidelines and comparisons with EU/EMEA and FDA/CVM standards. This is essential for understanding the regulations governing drugs approved in foreign countries and their implications under Swiss law on therapeutic products, established in December 2000.
E N D